Why Your PMCF Plan Is Not Ready for Market Surveillance

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

Under MDR, Post-Market Clinical Follow-up is no longer optional. Article 61(11) and Annex XIV Part B make it mandatory. But mandatory does not mean understood.

The shift from MDD to MDR changed what PMCF is supposed to do. It is no longer a post-approval documentation exercise. It is a continuous evaluation mechanism that feeds into clinical evaluation updates, risk management, and PSUR preparation.

Yet most PMCF plans still read like templates. They describe questionnaires, registry participation, and literature reviews. But they fail to show how the manufacturer will react when data suggests a safety signal, a performance deviation, or an emerging clinical trend.

That disconnect creates problems during audits and dossier reviews.

What Reviewers Look for in a PMCF Plan

When a Notified Body or competent authority reviews a PMCF plan, they are not checking if you have one. They are checking if it is functional.

A functional PMCF plan demonstrates that you understand your device’s residual uncertainty. It shows which clinical questions remain open after pre-market evaluation and explains how post-market data will address them.

MDCG 2020-7 makes this explicit. The PMCF plan must be tailored to the device, its risk profile, and the level of clinical evidence available at the time of initial certification.

If your device relies on equivalence, your PMCF plan should monitor whether clinical performance in real-world use aligns with the equivalent device. If your clinical data at submission was limited, your PMCF should actively collect outcomes to confirm safety and performance claims.

But here is the disconnect I see repeatedly:

This creates a plan that looks complete but cannot be executed. When a signal appears, there is no process to evaluate it. When a trend emerges in complaints, there is no defined response.

Reviewers notice this immediately.

PMCF Must Connect to Clinical Evaluation Updates

One of the most overlooked requirements is the linkage between PMCF and clinical evaluation.

MDR Article 61(11) states that PMCF is part of the manufacturer’s ongoing clinical evaluation. It is not separate. It is not parallel. It is integrated.

This means your PMCF plan must specify how collected data will be evaluated within the clinical evaluation framework. It must define who will review PMCF data, when it will be reviewed, and how findings will influence the Clinical Evaluation Report.

Most PMCF plans I review mention updating the CER, but they do not define the process. They do not explain how PMCF findings trigger an evaluation cycle. They do not describe what type of data would require an immediate update versus an annual review.

This is not theoretical. During surveillance audits, Notified Bodies will ask to see evidence that PMCF data has been evaluated and fed into the CER update process. If your PMCF plan does not define this workflow, the auditor will flag it.

Literature Monitoring Is Not Passive

Many PMCF plans state that the manufacturer will perform systematic literature reviews. This is required by MDCG 2020-6. But the way it is described often misses the point.

Literature monitoring under PMCF is not about finding supportive studies. It is about surveillance.

You are looking for signals. Adverse events reported with similar devices. New publications that challenge your performance claims. Meta-analyses that reveal risks not identified in pre-market data.

The PMCF plan must define search strategies, databases to be monitored, and review frequency. But more importantly, it must explain how identified literature will be assessed for relevance and what actions will be taken if relevant findings are identified.

Most plans I review say the manufacturer will “evaluate relevant literature.” That is not enough. Relevant to what? Evaluated by whom? What happens if the literature suggests a new risk or reduced clinical benefit?

If you do not define this in the PMCF plan, you create ambiguity. And ambiguity during an audit becomes a finding.

Real-World Evidence Must Be Defined

MDR pushes manufacturers toward collecting real-world evidence. PMCF is the mechanism to do this.

But real-world evidence is not a vague concept. It has to be structured.

Your PMCF plan must specify what data will be collected, from what sources, and how it will be analyzed. It must define endpoints. It must explain how you will ensure data quality and manage missing data.

This applies to registries, follow-up surveys, and even complaint analysis. If your PMCF plan says you will participate in a registry, it must describe what data the registry collects, how often data is extracted, and how it will be evaluated relative to the clinical claims in your CER.

If you plan to use surveys, the PMCF plan should describe the survey design, response rate expectations, and methods for handling non-responders.

These details matter because without them, the PMCF plan is aspirational. It describes what you intend to do but not how you will do it.

PMCF and Risk Management Must Align

Your PMCF plan does not exist in isolation. It must align with your risk management file.

If your risk analysis identifies residual risks that cannot be fully mitigated pre-market, those risks should drive PMCF objectives. Your PMCF plan should specify how post-market data will monitor those risks and confirm that the benefit-risk ratio remains acceptable.

This is not optional. ISO 14971:2019 requires manufacturers to collect and review production and post-production information. PMCF is how you do that for clinical risks.

But alignment is rarely explicit. I often see risk management files that identify residual risks and PMCF plans that describe data collection, but no clear connection between the two.

When a Notified Body reviews your dossier, they will look for that connection. They will check whether the PMCF plan addresses the clinical uncertainties flagged in the risk file. If the connection is missing, they will issue a finding.

When PMCF Becomes a Filing Problem

A weak PMCF plan creates downstream problems.

If your PMCF plan is vague, you cannot demonstrate that you are following it. If you cannot demonstrate compliance, your Notified Body may withhold certificate renewal or issue corrective actions.

If your PMCF plan does not connect to your CER updates, your clinical evaluation becomes static. You are no longer performing ongoing evaluation as required by MDR Article 61.

If your PMCF plan does not feed into your PSUR, you will struggle to complete Annex III requirements. PSURs require summary and analysis of PMCF data. If your PMCF plan does not define what data is collected or how it is analyzed, the PSUR becomes difficult to write.

This is the real cost of treating PMCF as a checkbox exercise. It does not fail immediately. It fails when you try to use it.

What a Functional PMCF Plan Looks Like

A functional PMCF plan is specific.

It defines objectives based on clinical uncertainty and residual risk. It specifies data sources, collection methods, and analysis intervals. It explains how findings will be evaluated and what actions will be triggered by specific types of data.

It links to the CER update process. It aligns with the risk management file. It provides enough detail that an external auditor can verify whether the plan is being followed.

It does not need to be long. It needs to be clear.

Closing Thought

PMCF under MDR is not about collecting data. It is about responding to what the data reveals.

If your PMCF plan does not define how you will respond, it is not ready for the post-market phase. And if it is not ready for the post-market phase, it will eventually become a compliance issue.

The question is not whether you have a PMCF plan. The question is whether your PMCF plan works.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.